, Volume 59, Issue 3, pp 565–572 | Cite as

Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer

  • Abbas Ali TamEmail author
  • Didem Ozdemir
  • Cevdet Aydın
  • Nagihan Bestepe
  • Serap Ulusoy
  • Nuran Sungu
  • Reyhan Ersoy
  • Bekir Cakir
Original Article



We aimed to investigate the relation between preoperative serum thyrotrophin (TSH) and clinicopathological features in patients with papillary thyroid carcinoma (PTC) and microcarcinoma (PTMC).


Patients who underwent thyroidectomy and diagnosed to have benign nodular disease or PTC/PTMC in our clinic were evaluated retrospectively. Patients with a previous history of thyroid surgery, patients using antithyroid medications or thyroid hormone and patients with tumors known to be unresponsive to TSH were excluded.


Data of 1632 patients were analyzed. Histopathological diagnosis was benign in 969 (59.4%) and malignant in 663 (40.6%) patients. Preoperative median serum TSH was significantly higher in malignant compared to benign group (1.41 IU/dL vs. 0.98 IU/dL, p < 0.001). Malignancy risk increased gradually as going from hyperthyroidism to euthyroidism and hypothyroidism (20, 40.6, and 59.1%, respectively, p < 0.05). Serum TSH was lowest in benign nodular disease, higher in PTMC and highest in PTC (p < 0.001). This was also true when patients with positive antithyroid peroxidase/antithyroglobulin and with lymphocytic thyroiditis were excluded from the analysis (p < 0.001). Serum TSH was higher in patients with bilateral tumor, capsular invasion and lymph node metastasis (LNM) compared to patients with unilateral tumor, without capsule invasion and without LNM, respectively (p = 0.036, p = 0.002, and p = 0.001, respectively). Patients with aggressive variant PTC had higher serum TSH than nonaggressive ones (p < 0.05).


Preoperative serum TSH is associated with PTMC, PTC and LNM. Serum TSH seems to be related with thyroid cancer regardless of autoimmunity. With the present study, for the first time, we showed an association between serum TSH and aggressive variants of PTC.


Thyrotrophin Papillary thyroid cancer Autoimmunity Lymph node metastasis Aggressive variants 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    L.Z. He, T.S. Zeng, L. Pu, S.X. Pan, W.F. Xia, L.L. Chen, Thyroid hormones, autoantibodies, ultrasonography, and clinical parameters for predicting thyroid cancer. Int. J. Endocrinol. 2016, 8215834 (2016)CrossRefGoogle Scholar
  2. 2.
    C. Li, W. Yu, J. Fan et al., Thyroid functional parameters and correlative autoantibodies as prognostic factors for differentiated thyroid cancers. Oncotarget 7, 49930–49938 (2016)PubMedPubMedCentralGoogle Scholar
  3. 3.
    D.S. McLeod, D.S. Cooper, P.W. Ladenson et al.,Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid 24, 35–42 (2014)CrossRefGoogle Scholar
  4. 4.
    K. Boelaert, The association between serum TSH concentration and thyroid cancer. Endocr. Relat. Cancer 16, 1065–1072 (2009)CrossRefGoogle Scholar
  5. 5.
    P. Pujol, J.P. Daures, N. Nsakala et al., Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 81, 4318–4323 (1996)PubMedGoogle Scholar
  6. 6.
    E.L. Mazzaferri, S.M. Jhiang, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418–428 (1994)CrossRefGoogle Scholar
  7. 7.
    E. Fiore, P. Vitti, Serum, TSH and risk of papillary thyroid cancer in nodular thyroid disease. J. Clin. Endocrinol. Metab. 97, 1134–1145 (2012)CrossRefGoogle Scholar
  8. 8.
    C. Zafon, G. Obiols, J.A. Baena et al., Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. J. Thyroid. Res. 2012, 530721 (2012)CrossRefGoogle Scholar
  9. 9.
    D.P. Momesso, R.M. Tuttle, Update on differentiated thyroid cancer staging. Endocrinol. Metab. Clin. North Am. 43, 401–421 (2014)CrossRefGoogle Scholar
  10. 10.
    M.R. Haymart, D.J. Repplinger, G.E. Leverson et al., Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J. Clin. Endocrinol. Metab. 93, 809–814 (2008)CrossRefGoogle Scholar
  11. 11.
    K. Boelaert, J. Horacek, R.L. Holder et al., Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J. Clin. Endocrinol. Metab. 91, 4295–4301 (2006)CrossRefGoogle Scholar
  12. 12.
    H.K. Kim, J.H. Yoon, S.J. Kim et al., Higher TSH level is a risk factor for differentiated thyroid cancer. Clin. Endocrinol. 78, 472–477 (2013)CrossRefGoogle Scholar
  13. 13.
    K.W. Kim, Y.J. Park, E.H. Kim et al., Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto’s thyroiditis. Head. Neck. 33, 691–695 (2011)CrossRefGoogle Scholar
  14. 14.
    M.R. Castro, R.P. Espiritu, R.S. Bahn et al., Predictors of malignancy in patients with cytologically suspicious thyroid nodules. Thyroid 21, 1191–1198 (2011)CrossRefGoogle Scholar
  15. 15.
    S. Rinaldi, M. Plummer, C. Biessy et al., Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J. Natl. Cancer Inst. 106, dju097 (2014)CrossRefGoogle Scholar
  16. 16.
    A. Dorange, S. Triau, S. Mucci-Hennekinne et al., An elevated level of TSH might be predictive of differentiated thyroid cancer. Ann. Endocrinol. 72, 513–521 (2011)CrossRefGoogle Scholar
  17. 17.
    A.T. Franco, R. Malaguarnera, S. Refetoff et al., Thyrotrophin receptor signaling dependence of Braf‐induced thyroid tumor initiation in mice. Proc. Natl. Acad. Sci. USA 108, 1615–1620 (2011)CrossRefGoogle Scholar
  18. 18.
    M. Gerschpacher, C. Göbl, C. Anderwald et al., Thyrotropin serum concentrations in patients with papillary thyroid microcancers. Thyroid 20, 389–392 (2010)CrossRefGoogle Scholar
  19. 19.
    R. Negro, R. Valcavi, F. Riganti et al., Thyrotropin values in patients with micropapillary thyroid cancer versus benign nodular disease. Endocr. Pract. 19, 651–655 (2013)CrossRefGoogle Scholar
  20. 20.
    L. Shi, Y. Li, H. Guan et al., Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1,870 Chinese patients with thyroid nodules. Endocr. J. 59, 973–980 (2012)CrossRefGoogle Scholar
  21. 21.
    J.S. Choi, C.M. Nam, E.K. Kim et al., Evaluation of serum thyroid-stimulating hormone as indicator for fine-needle aspiration in patients with thyroid nodules. Head. Neck. 37, 498–504 (2015)CrossRefGoogle Scholar
  22. 22.
    R.L. Shi, T. Liao, N. Qu et al., The usefulness of preoperative thyroid stimulating hormone for predicting differentiated thyroid microcarcinoma. Otolaryngol. Head. Neck. Surg. 154, 256–262 (2016)CrossRefGoogle Scholar
  23. 23.
    J. Zheng, C. Li, W. Lu et al., Quantitative assessment of preoperative serum thyrotropin level and thyroid cancer. Oncotarget 7, 34918–34929 (2016)PubMedPubMedCentralGoogle Scholar
  24. 24.
    E. Fiore, T. Rago, M.A. Provenzale et al., Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: Thyroid autonomy may play a protective role. Endocr. Relat. Cancer 16, 1251–1260 (2009)CrossRefGoogle Scholar
  25. 25.
    D.S. McLeod, K.F. Watters, A.D. Carpenter et al., Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J. Clin. Endocrinol. Metab. 97, 2682–2692 (2012)CrossRefGoogle Scholar
  26. 26.
    C.E. Silver, R.P. Owen, J.P. Rodrigo et al., Aggressive variants of papillary thyroid carcinoma. Head. Neck. 33, 1052–1059 (2011)CrossRefGoogle Scholar
  27. 27.
    X. Shi, R. Liu, F. Basolo et al., Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J. Clin. Endocrinol. Metab. 101, 264–274 (2016)CrossRefGoogle Scholar
  28. 28.
    J. Jonklaas, H. Nsouli-Maktabi, S.J. Soldin, Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid 18, 943–952 (2008)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Endocrinology and MetabolismYıldırım Beyazıt University Faculty of MedicineAnkaraTurkey
  2. 2.Department of SurgeryAtaturk Training and Research HospitalAnkaraTurkey
  3. 3.Department of PathologyYıldırım Beyazıt University Faculty of MedicineAnkaraTurkey

Personalised recommendations